Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1391740-89-8

ethyl 4-(4-methoxybenzylamino)-6-chloropyridine-3-carboxylate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1391740-89-8 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1391740-89-8 Structure

  • Basic information

    1. Product Name: ethyl 4-(4-methoxybenzylamino)-6-chloropyridine-3-carboxylate
    2. Synonyms: ethyl 4-(4-methoxybenzylamino)-6-chloropyridine-3-carboxylate
    3. CAS NO:1391740-89-8
    4. Molecular Formula:
    5. Molecular Weight: 320.776
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1391740-89-8.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: ethyl 4-(4-methoxybenzylamino)-6-chloropyridine-3-carboxylate(CAS DataBase Reference)
    10. NIST Chemistry Reference: ethyl 4-(4-methoxybenzylamino)-6-chloropyridine-3-carboxylate(1391740-89-8)
    11. EPA Substance Registry System: ethyl 4-(4-methoxybenzylamino)-6-chloropyridine-3-carboxylate(1391740-89-8)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1391740-89-8(Hazardous Substances Data)

1391740-89-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1391740-89-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,9,1,7,4 and 0 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1391740-89:
(9*1)+(8*3)+(7*9)+(6*1)+(5*7)+(4*4)+(3*0)+(2*8)+(1*9)=178
178 % 10 = 8
So 1391740-89-8 is a valid CAS Registry Number.

1391740-89-8Relevant articles and documents

NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS

-

Paragraph 0223, (2020/10/20)

The present invention discloses compounds according to Formula (I): (I). Wherein R1, R2, R5 and Cy are as defined herein. The present invention relates to compounds, methods for the production of said compounds, pharmaceutical compositions comprising said compounds and methods for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, pain, fibrosis and/or proliferative diseases by administering said compounds.

Synthetic method for 4-bromo-6-chloronicotinaldehyde

-

Paragraph 0035; 0041-0043; 0052; 0053; 0054; 0063; 0064, (2019/05/08)

The invention provides a synthetic method for 4-bromo-6-chloronicotinaldehyde, and relates to the field of pharmaceutical chemistry. A synthetic route includes as follows: ethyl 6-chloro-4-((4-methoxybenzyl)amino)nicotinate can be obtained through the rea

CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS

-

Page/Page column 51, (2019/01/08)

A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3- d ]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells

Henry, James R.,Kaufman, Michael D.,Peng, Sheng-Bin,Ahn, Yu Mi,Caldwell, Timothy M.,Vogeti, Lakshminarayana,Telikepalli, Hanumaiah,Lu, Wei-Ping,Hood, Molly M.,Rutkoski, Thomas J.,Smith, Bryan D.,Vogeti, Subha,Miller, David,Wise, Scott C.,Chun, Lawrence,Zhang, Xiaoyi,Zhang, Youyan,Kays, Lisa,Hipskind, Philip A.,Wrobleski, Aaron D.,Lobb, Karen L.,Clay, Julia M.,Cohen, Jeffrey D.,Walgren, Jennie L.,McCann, Denis,Patel, Phenil,Clawson, David K.,Guo, Sherry,Manglicmot, Danalyn,Groshong, Chris,Logan, Cheyenne,Starling, James J.,Flynn, Daniel L.

supporting information, p. 4165 - 4179 (2015/06/08)

The RAS-RAF-MEK-MAPK cascade is an essential signaling pathway, with activation typically mediated through cell surface receptors. The kinase inhibitors vemurafenib and dabrafenib, which target oncogenic BRAF V600E, have shown significant clinical efficac

QUINAZOLINONE DERIVATIVE

-

Paragraph 0134, (2016/10/08)

PROBLEM TO BE SOLVED: To provide a novel compound having effects on 5-HT5A receptor and useful as a therapeutic agent and/or a preventive agent of psychiatric disorders and neurodegenerative diseases to which 5-HT5A receptor relates such as schizophrenia,

RAF INHIBITOR COMPOUNDS

-

Page/Page column 39, (2013/09/26)

This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1391740-89-8